ArticleEuropean journal of clinical pharmacology2024
Real-world characteristics and use patterns of patients treated with vericiguat: A nationwide longitudinal cohort study in Germany.
Article in European journal of clinical pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 18 citations in OpenAlex.
- Vericiguat in Elderly Patients with Heart Failure and Reduced Ejection Fraction: Clinical Perspectives from Pathophysiology to Implementation.Journal of clinical medicine · 2026Review
- One-year multicenter prospective real-world study of vericiguat effectiveness and safety in Spain.ESC heart failure · 2026Observational
- Association Between Different Vericiguat Dose Exposures, Concomitant Quadruple Heart Failure Therapy, and Myocardial Fibrosis Burden in Older Adults with Worsening Heart Failure with Reduced Ejection Fraction.Anatolian journal of cardiology · 2026Article
- One-year real-world outcomes after vericiguat initiation in heart failure: The ROVER-Japan cohort study.International journal of cardiology. Heart & vasculature · 2026Article
- Vericiguat: A New Horizon for Heart Failure Treatment.Reviews in cardiovascular medicine · 2026Review
- Association of Vericiguat with Improvement in Functional Abilities and Comprehensive Geriatric Assessment in Elderly Patients with Worsening Heart Failure.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Initiation, titration, and safety of vericiguat for treatment of heart failure in United States clinical practice.American heart journal plus : cardiology research and practice · 2026Article
- Estimating the Benefits of the Comprehensive Disease-modifying Pharmacological Treatment in Patients with Heart Failure.Cardiac failure review · 2026Review
- Efficacy and Safety of Vericiguat in a Real-life Population with Heart Failure after 1 Year of Treatment: The VERITA Study.Cardiac failure review · 2026Article
- Article
- The Role of Vericiguat in Heart Failure Therapy: From Clinical Trials to Clinical Practice.Reviews in cardiovascular medicine · 2025Review
- Sex differences in diagnosis and treatment of heart failure: toward precision medicine.The Korean journal of internal medicine · 2025Review
- Effectiveness and safety of vericiguat in patients with heart failure and reduced ejection fraction: a narrative review of real-world evidence studies.Frontiers in cardiovascular medicine · 2025Review
- Clinical profile, associated events and safety of vericiguat in a real-world cohort: The VERITA study.ESC heart failure · 2024Observational
- New Therapeutics for Heart Failure Worsening: Focus on Vericiguat.Journal of clinical medicine · 2024Review
- Towards the Fifth Pillar for the Treatment of Heart Failure with Reduced Ejection Fraction: Vericiguat in Older and Complex Patients.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024Review
- Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial.Frontiers in cardiovascular medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeVericiguat reduced clinical endpoints in patients experiencing worsening heart failure in clinical trials, but its implementation outside trials is unclear.
methodsThis retrospective analysis of longitudinally collected data was based on the IQVIA™ LRx database, which includes ~ 80% of the prescriptions of the 73 million people covered by the German statutory health insurance.
resultsBetween September 2021 and December 2022, vericiguat was initiated in 2916 adult patients. Their mean age was 73 ± 13 years and 28% were women. While approximately 70% were uptitrated beyond 2.5 mg, only 36% reached 10 mg. Median time to up-titration from 2.5 mg to 5 mg was 17 (quartiles: 11-33) days, and from 2.5 to 10 mg 37 (25-64) days, respectively. In 87% of the patients, adherence to vericiguat was high as indicated by a medication possession ratio of ≥ 80%, and 67% of the patients persistently used vericiguat during the first year. Women and older patients reached the maximal dose of 10 mg vericiguat less often and received other substance classes of guideline-recommended therapy (GDMT) less frequently. The proportion of patients receiving four pillars of GDMT increased from 29% before vericiguat initiation to 44% afterwards.
conclusionIn a real-world setting, despite higher age than in clinical trials, adherence and persistence of vericiguat appeared satisfactory across age categories. Initiation of vericiguat was associated with intensification of concomitant GDMT. Nevertheless, barriers to vericiguat up-titration and implementation of other GDMT, applying in particular to women and elderly patients, need to be investigated further.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.